MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

Search

Bayer AG

Geschlossen

BrancheFinanzen

22.87 0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.835

Max

23.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.9B

-335M

Verkäufe

1.8B

12B

KGV

Branchendurchschnitt

30.9

24.598

EPS

1.05

Dividendenrendite

0.47

Gewinnspanne

-2.856

Angestellte

90,587

EBITDA

615M

1.7B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+14.57% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.47%

4.30%

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.4B

24B

Vorheriger Eröffnungskurs

22.72

Vorheriger Schlusskurs

22.87

Nachrichtenstimmung

By Acuity

29%

71%

77 / 540 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Bayer AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2025, 08:22 UTC

Ergebnisse
Wichtige Markttreiber

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13. Mai 2025, 06:09 UTC

Ergebnisse

Bayer Confirms Guidance Despite Net Profit Drop

24. März 2025, 09:37 UTC

Wichtige Markttreiber

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5. März 2025, 11:21 UTC

Ergebnisse

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5. März 2025, 08:45 UTC

Ergebnisse

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13. Mai 2025, 06:50 UTC

Market Talk
Ergebnisse

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13. Mai 2025, 05:36 UTC

Ergebnisse

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13. Mai 2025, 05:35 UTC

Ergebnisse

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13. Mai 2025, 05:34 UTC

Ergebnisse

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13. Mai 2025, 05:34 UTC

Ergebnisse

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13. Mai 2025, 05:32 UTC

Ergebnisse

Bayer 1Q EPS EUR2.49

13. Mai 2025, 05:32 UTC

Ergebnisse

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13. Mai 2025, 05:32 UTC

Ergebnisse

Bayer 1Q Ebitda Before Special Items EUR4.085B

13. Mai 2025, 05:31 UTC

Ergebnisse

Bayer 1Q EBIT EUR2.32B

13. Mai 2025, 05:31 UTC

Ergebnisse

Bayer 1Q Net Pft EUR1.30B

13. Mai 2025, 05:31 UTC

Ergebnisse

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13. Mai 2025, 05:30 UTC

Ergebnisse

Analysts Saw Bayer 1Q Sales at EUR13.41B

13. Mai 2025, 05:30 UTC

Ergebnisse

Bayer 1Q Sales EUR13.74B

13. Mai 2025, 05:30 UTC

Ergebnisse

Bayer Backs 2025 View

14. Apr. 2025, 13:00 UTC

Top News

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7. Apr. 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10. März 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5. März 2025, 13:39 UTC

Market Talk
Ergebnisse

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5. März 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5. März 2025, 08:30 UTC

Market Talk
Ergebnisse

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

Peer-Vergleich

Kursveränderung

Bayer AG Prognose

Kursziel

By TipRanks

14.57% Vorteil

12-Monats-Prognose

Durchschnitt 26.19 EUR  14.57%

Hoch 33 EUR

Tief 20 EUR

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bayer AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

2

Buy

10

Halten

0

Sell

Technischer Score

By Trading Central

22.99 / 23.88Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

77 / 540 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.